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abdominal aortic aneurysms
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Introduction: Abdominal aortic aneurysms (AAA) are associated with inflammation, apoptosis, andmatrix degradation. AAA
tissue represents the end stage of disease, limiting its utility in identification of factors culpable for initiation of aneurysm
development. Recent evidence suggests that AAAs are a local representation of a systemic disease of the vasculature.
Morphologic and molecular changes, comparable to those found in the aneurysm wall, have been demonstrated in veins from
patients with AAAs. Changes in the vascular tissue proteome of patients with AAAs were investigated, using inferior
mesenteric vein (IMV), to gain insight into early molecular changes contributing to AAA development.
Methods: IMV was harvested from 16 patients with AAA and 16 matched controls. Whole IMV lysates were subjected to
2-D difference in gel electrophoresis (2D-DIGE) with quantitative densitometry. Protein spots differentially expressed in
AAA were identified using mass spectrometry. Differential protein expression was validated by Western blotting and
localized to cell type by immunohistochemistry (IHC).
Results: Decreased levels of prohibitin (AAA, 2.00  1.37; controls, 3.81  1.39; 1.9-fold change; P  .02) AAA
(7.33  3.9; controls, 14.5  5.6; 2-fold change; P  .001), along with relative increases in a cleaved fragment of
vimentin (AAA, 12.9 9; controls, 6.9 4.7; 2-fold change; P .11) were identified in AAA patients. All proteins were
localized to the vascular smooth muscle cells.
Conclusions: Proteins important in combating the injurious effects of oxidative stress and modulating the response to
inflammation appear reduced in the vasculature of patients with AAA. These changes may represent early events in AAA
formation. Enhancing expression of these proteins might offer a novel therapeutic avenue to inhibit AAA development.
(J Vasc Surg 2011;54:1100-8.)
Clinical Relevance: AAA is a preventable cause of death. Molecular and histological studies have provided great insight into
the features of large aneurysms.However, little is known about factors initiating aneurysm development. Genetic studies have
failed to identify causal genes or specific nucleotide polymorphisms culpable for aneurysm initiation. Proteomics provides an
insight into cellular changes down-stream of genetic code. This study uses proteomic techniques to establish protein changes
in the vasculature that may be involved in AAA development. The future of AAA treatment may be pharmacological whereby














tAbdominal aortic aneurysms (AAA) are characterized
by local inflammation, matrix degradation, and smooth
muscle cell (SMC) apoptosis.1-3 Aneurysmal vessels dem-
onstrate arterial dilatation, wall thickening, and a dramatic
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1100eduction in the elastin/collagen ratio.4,5 The matrix deg-
adation results from excessive production of matrix metal-
oproteinases (MMP), with MMP-2 the dominant elastase
n small aneurysms.6,7 Despite evolving understanding of
AA pathogenesis, as the majority of our current informa-
ion is derived from analysis of mature AAA biopsies, elu-
idation of factors that initiate aneurysm development has
roved difficult.
Molecular mechanisms of AAA formation and the
reatment of small aneurysms are the subject of intensive
esearch. Family history is a risk factor for AAA develop-
ent independent of atherosclerosis.8 This has led to a
eries of candidate gene explorations of biologically plausi-
le pathways9 and a recent genome-wide association study
o identify variations in single nucleotide polymorphisms
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Volume 54, Number 4 Nordon et al 1101failed to discover novel genes or protein signaling pathways
that could translate into biomarkers or therapeutic strate-
gies to combat AAA development or rupture. Proteomic
techniques can be applied to identify specific protein mod-
ifications downstream of genetic code and may provide
novel important insights into AAA pathogenesis.
The key limitation in mining the proteome of AAA, as
with all molecular biological approaches, lies in availability
of appropriate substrate. AAA tissue represents the end-
stage of disease, and comparative analysis is limited by the
availability of suitable matched control tissue. Cadaveric
and organ-donor tissue samples are invariably poorly age-
and comorbidity-matched. Even with well-matched con-
trols, the molecular changes in these tissues demonstrate
the late phase of AAA pathogenesis with necrosis, calcifica-
tion, and acellular amorphous tissue. This provides no
insight into mechanisms initiating AAA development. Se-
rum and plasma proteomic analysis has thus far failed to
yield putative biomarkers of AAA or add to understanding
of disease pathogenesis.11
There is evidence that the entire vascular tree is abnor-
mal in patients with aneurysmal disease.12 Patients with
AAA exhibit arterial dilatation and altered matrix composi-
tion throughout the vasculature.13,14 Elevation of MMP-2
occurs in arteries and veins remote from the aorta in pa-
tients with AAA,15 and AAA are associated with generalized
arteriomegaly,16 carotid artery dilatation,14 and coronary
artery ectasia.17
The inferior mesenteric vein (IMV) has been used as a
tissue model of early aneurysmal changes previously. Dis-
ruption and reduction of elastin occurs in the veins of
patients with AAAs in a similar fashion to that observed in
the aneurysm wall.18 The benefit of utilizing this tissue is
that it is free from atherosclerosis, rendering any changes in
the proteome attributable to systemic changes in the vas-
culature associated with AAA. Protein expression changes
in venous tissue have been shown to be a reliable surrogate
for those in arterial tissue.19 Equally, the molecular regula-
tion of oxidative stress in human vascular disease has been
shown to be systemic with corresponding oxidase activity in
veins and arteries.20
The purpose of this study was to assess differences
between the protein profile in the vasculature of patients
with AAA and matched controls. The identification of
specific protein alterations associated with AAA by pro-
teomic mining may add to the understanding of the patho-
genesis, provide further evidence of a systemic disease of
the vasculature, and guide future pharmacotherapeutic
strategies.
METHODS
Source of tissue. The study was performed between
December 2008 and January 2010. A segment of IMV was
obtained from 16 patients with large AAAs at the time of
open AAA repair. Control samples from 16 contemporary
patients were obtained from patients undergoing left hemi-
colectomy for benign colonic pathology (confirmed on
histology). The site of IMV harvest and specimen size was oonsistent across both groups; vein was harvested from the
ain IMV trunk (proximal to tributaries). AAA patients
ere excluded if they had inflammatory aneurysms, known
alignancy, active colitis, or had previous left hemicolec-
omy. Control patients were excluded if they had an active
nflammatory process, current steroid therapy, prior che-
otherapy, or an AAA visible on preoperative imaging.
ritten informed consent was obtained from all patients,
nd received local ethics committee approval (ref 08/
0803/210).
IMV was dissected from the colonic mesentery. The
resh samples were irrigated with saline and stripped of
ccessory connective tissue. Samples were immediately
nap-frozen in liquid nitrogen and stored at 80°C until
rotein analysis.
Protein extraction. Frozen IMV was homogenized
nder liquid nitrogen with pestle andmortar. Proteins were
hen solubulized in lysis buffer. After tissue disruption and
ellular lysis, samples were centrifuged at 10,000 rpm, 4°C
or 10 minutes. Protein concentration of the supernatant
as determined by modified Bradford assay (Bio-Rad, San
rancisco, Calif).21 Fifty micrograms of total protein per
ample were analyzed.
Dimensional differential gel electrophoresis. Equal
mounts of IMV protein (50 g) from AAA patients and
ontrols were independently labeled with Cy3 (Cyanine)
ye and Cy5 dye, respectively; lysine quenched the labeling
eaction (minimal label method).22 An internal standard
IS) containing equal amounts of each sample (cases and
ontrols) was tagged with Cy2 dye; this ensures consistent
omparison across the two groups, removing gel-gel vari-
bility. Labeled protein samples (AAA, control, and inter-
al standard) were loaded onto immobilized pH gradient
ry strips with a non-linear pH range of pH 3-11 (GE
ealthcare, Amersham,UK). After isoelectric focusing (to-
al 73kVh), the strips were equilibrated with dithiotreitol
nd iodoacetamide equilibration buffers sequentially.
econd dimension separation was conducted with 12.5%
DS-polyacrylamide gel electrophoresis at 6.7 W/gel for
8 hours. Twenty gels were run in total: 16 unique
omparative gels (AAA/Control/IS) and four unlabeled
els for protein identification. Ten gels were run simul-
aneously. Gels for future protein picking contained 500
g of unlabeled protein.
Image analysis. Labeled proteins were visualized on
he gel using a Typhoon 9400 scanner (GE Healthcare).
pot matching, quantification, and statistical analyses were
erformed using Progenesis Samespots software (Nonlin-
ar Dynamics, Newcastle, UK). Scanned images were up-
oaded into the software, and automated alignment, spot
etection, and quantification were performed. Computer
etected spots were listed by fold change and statistical
ignificance. Spots were manually validated for morpho-
ogic consistency and location on the gel. Only spots with
onsistent morphology and located in the field of interest
ere further investigated. The Samespots software gener-
ted a normalized intensity value for each spot. These values
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Protein spotswere considered to be significantly differentiated
when the t test value was P  .05, and the fold change was
greater than 1.5. Further details of difference in gel electro-
phoresis (DIGE) experiment available at http://miapegeldb.
expasy.org/experiment/87/.
Mass spectrometry (MS) and protein identification.
Protein spot candidates were mechanically picked from a
silver stained picking gel by a Propicker (Genomic Solu-
tions, Holliston, Mass) and trypsin digested. Eluted pep-
tides were identified preferentially by liquid chromatogra-
phy mass spectrometry (ThermoFinnigan, San Jose, Calif)
and secondly by matrix-assisted laser desorption ionization
time-of-flight mass spectrometry (MALDI-TOF; Bruker,
Madison, Wisc). MS/MS spectra were searched using the
Seaquest and Matrix Science search databases (http://
www.matrixscience.com). Raw data were uploaded to Pro-
teomics Identifications Database (PRIDE) in accordance
with MIAPE (Minimum Information About Proteomic
Experiments) guidelines (http://www.ebi.ac.uk/pride).
Vimentin fragment (LCQ) protein identification was based
on Xc score1, P .0001, and manual inspection to ensure
sequences was consistent with ion fragments. Probability-
based mascot score56 was considered significant (P .05)
for MALDI-TOF identified proteins.23
Immunoblotting. Protein specific validation of find-
ings on the 2-D gels was performed. Relative abundance of
differentially expressed proteins was examined by Western
blotting.24 AAA patient protein lysates were compared
with controls. Fifty micrograms protein extract in lysis
buffer was loaded onto 12% SDS-PAGE gels and separated
by electrophoresis. Proteins were electroblotted onto poly-
vinylidene fluoride membrane (Hybond; GE Healthcare).
Antibodies against prohibitin (Clone EP2804Y; Epitomics,
Burlingame, Calif), annexin A1 (Peptide ID P07801; Aviva
Systems Biology, San Diego, Calif) and caspase-cleaved
vimentin (Cleavage site Asp259; MBL International,
Woburn, Mass) were used. Positive controls (not shown)
included recombinant human annexin A1 (Insight Bio-
technology Ltd, London, UK) and whole cell lysate (Santa
Cruz Biotechnology, Santa Cruz, Calif). Positive immuno-
reactivity was detected with chemoluminescence substrate
(ECL Plus, GE Healthcare) and exposure of the blots to
film (Hyperfilm, GE Healthcare). After development, films
were digitized, and quantitative densitometric image anal-
ysis was performed (ID Kodak Software, San Diego, Calif).
To exclude intrapatient variability, each Western blot gel
was generated in duplicate and analyzed independently.
Immunohistochemistry (IHC). Standardized IHC
methodology was used to localize the protein expression in
the tissue; no quantitative IHC was performed.25 Frozen
IMV segments were cut into 6-m sections for indirect
immunohistochemical analysis. Tissue was fixed in chilled
acetone, permeabilized in 1% hydrogen peroxide, and
blocked with 20% fetal calf serum (FCS). Primary antibody
exposure, using antibodies as described above, was per-
formed for 1 hour. Further incubation with biotinylated
secondary antibody coupled with streptavidin-horseradish reroxidase (Dako, Glostrup, Denmark) was performed fol-
owed by antibody localization with DAB chromogen
Dako). Tissue sections were stained with anti-CD34 (en-
othelial cells) and anti--smooth muscle actin antibodies
VSMCs) to localize cell types. The distribution of protein
pecific antibodies was then compared with the control
tains.
Statistics. A prestudy power calculation was per-
ormed based on previous serum proteomic analysis within
he group (in this study, the principal component analysis
f the statistically significant protein hits generated a coef-
cient of variation [CV] of 40%). The DIGE technique
nsured that gel-to-gel variation was nil. Incorporating
stimates for biological and technical variability, it was
stimated that a minimum of 16 samples from each group
as required to be confident of identifying a 1.5-fold
hange (50% effect size) with type 1 error rate set at 0.05
ith 80% power (power was naturally limited by availability
f biological samples).
Statistical significance of densitometry values between
roups for known proteins was determined by computing
he paired t test P value. The P values from the paired t tests
ere used to determine the significant increase/decreases
ontrolling for the false discovery rate (FDR) attributable
o multiple comparisons. This method determines a Q
alue (modified P value) for statistical significance based on
he number of other spots at that given significance thresh-
ld or less, reducing the likelihood of false discovery with-
ut being as conservative as the traditional Bonferroni
pproach. The FDR was provisionally set at 0.2. This level
as set following consideration of conventional practice,
he desire not to miss too many real differences, and the
esire to limit false positives.26 As protein changes were
xpected to be subtle, following manual analysis of the data
et, spots outside this limit were selected for further valida-
ion providing the t test P value was significant and visual
alidation confirmed a well-defined protein spot. This was
erformed on the understanding that only spots with pro-
ein specific validation would be considered significant.
ESULTS
Patient characteristics. A total of 16 patients were
able I. Patient demographics for inferior mesenteric






ender (male; female) 10:6 8:8 .72
ge 70.6 (6.6) 70.3 (7.5) .90
urrent smoking 4/16 3/16 1.0
ypertension 8/16 6/16 .72
iabetes 2/16 1/16 1.0
tatin therapy 11/16 6/16 .16
ean aortic diameter (cm) 6.7 (0.9) 2.0 (0.2) .0001
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Volume 54, Number 4 Nordon et al 1103balanced for gender (P  .72), age (P  .90), current
smoking (P  1.0), and statin therapy (P  .16).
Differentially expressed proteins in AAAS. Sixteen
comparative 2-D gels were run, alongside four picking gels
(500 g) for protein identification. The Progenesis Same-
spots software identified 1217 independent spots on the
gels. The automated (computer software-driven) analysis
identified 118 spots that demonstrated statistically signifi-
cant differential expression (P  .05). Manual filtering
reduced this to 103 spots by excluding artifact and spots
outside the region of interest. Combining factors of fold
change (1.5 [34 spots]), statistical significance (P  .05
[16 spots]), and manual filtering (consistency of spot mor-
phology and intensity), 10 spots of interest worthy of
identification and further validation, based on the three
factors mentioned, were identified. Of these 10 protein
spots, two were up-regulated in AAA disease and eight
downregulated (Table II). From the aligned silver-stained
gels, the 10 spots were subjected to mass spectrometry.
Four of 10 protein spots (Fig 1) were identified byMS/MS
spectra; in the remaining six of 10, no positive identification
was obtained. No successful identification of these spots
was achieved despite increasing volumes of protein in the
“picking gels” and repeated MS analysis. The protein spots
identified are detailed in Table III. Details of the mass
spectrometric identification along with the mass spectra
outputs are summarized in the Supplemental information
(Supplemental Figs 1-6 and Supplemental Table, online
only). The confirmed up-regulated protein was vimentin.
The downregulated proteins were prohibitin, annexin
A1, and -cardiac actin. Comparison of the molecular
weight of separated proteins with theoretic values and
analysis of the sequence coverage achieved by mass spec-
trometry revealed that vimentin was not up-regulated as
a whole protein but as a cleaved fragment. The signifi-
cant change in -cardiac actin was not pursued further,
as it is a highly conserved structural protein involved in
cell contractility and motility without teleologic signifi-
cance in AAA formation. Therefore, three proteins at-
tracted interest in relation to their role in AAA patho-






640 7.153e-005 0.035 1.6 1.131
499 7.547e-005 0.035 2.6 2.044
506 6.545e-004 0.07 2.1 1.676
677 0.002 0.09 1.5 1.162
744 0.002 0.09 1.6 1.385
1171 0.003 0.12 2.7 1.458
1179 0.004 0.13 3.5 2.019
1090 0.004 0.13 2.5 0.897
1144 0.016 0.24 1.6 0.874
1083 0.044 0.34 1.5 1.491
AAA, Abdominal aortic aneurysm; ANOVA, analysis of variance.
aRelative normalized concentrations.
bMascot score following matrix-assisted laser desorption/ionization-time ogenesis, prohibitin, annexin A1, and cleaved vimentin. bValidation by immunoblotting. Downregulation of
rohibitin was confirmed by Western blotting (AAA,
.00  1.37; controls, 3.81  1.39; 1.9-fold change; P 
02; Fig 2). Similarly, downregulation of annexin A1 was
onfirmed (AAA, 7.33  3.9; controls, 14.5  5.6; 2-fold
hange; P  .001).
Validation of vimentin by Western blot demonstrated a
eries of non-specific bands. The observation led to further
xploration of the possible significance of cleaved vimentin.
he intermediate filament protein vimentin has been identi-
ed as a caspase substrate. During apoptosis, vimentin is
leaved by multiple activated caspases, including caspase-3,
6, and -9 to yield proteolytic fragments. The initial cut is
ade at Asp259 by caspase-9 inducing two fragments, a
1kDa and a 21kDa fragment. The vimentin spot on the
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1 Vimentin 1.5e-006 —
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(V1) confirmed differential expression with a mean fold
change of x1.9 (AAA, 12.9 9; controls, 6.9 4.7; 2-fold
change; P  .11).
Localization of protein expression. IHC analysis to
localize protein expression to cell type as whole tissue lysate
was used for proteomic analysis; no quantitative IHC was
performed. Fig 3 shows how all proteins, prohibitin, an-
nexin A1, and cleaved vimentin demonstrate the same
pattern of distribution within the IMV samples as
-smooth muscle actin. This localized to the vessel media
and a small volume of longitudinal bundles corresponding
to the VSMC.
DISCUSSION
Tissue proteomics seeks to identify differential protein
expression as a function of a disease state. The present study
is the first to demonstrate differential protein expression in
the systemic vasculature of patients with AAA compared
with a cohort of well-matched controls. In the proteomic
comparison, 103 protein spots demonstrated significant
differential expression, and of these, 72 were decreased in
the aneurysm group. This finding raised the suspicion that
a deficiency in one or a group of proteins may predispose
Table III. Reference values and proposed function of pro
Spot
number Protein Uniprot ref
Theoreti
(kDa
499 -cardiac actin P68032 42
677 Annexin A1 P04083 38.7
744 Prohibitin P35232 29.8
1144 Vimentin P08670 53.5
Fig 2. Western blot validation of differential protein expatients to AAA development; a systemic susceptibility. Ihe proteins that have been identified are generally consid-
red to be ubiquitous, and have been implicated in regula-
ion of inflammation, cellular senescence, oxidative stress,
nd apoptosis.27,28
One of the key challenges in aneurysm research has
een to elucidate factors that initiate aneurysm develop-
ent. AAAs are generally asymptomatic until they rupture.
stablished aortic aneurysms exhibit features of end-stage
isease and are largely acellular, matrix-rich, and with areas
f necrosis and atherosclerosis. These factors limit the
tility of aneurysm wall in comparative proteomic mining.
Any hypothesis that aims to define the early molecular
vents of the aneurysmal process must explain the transition
rom normal healthy, cell-rich, aortic wall to the end-stage
egeneration of an established aneurysm. The present
tudy utilized tissue remote from the aneurysm wall in an
ffort to analyze vasculature that had not been completely
egraded by the aneurysmal process. This approach has
reviously been justified, as aortic aneurysms represent a
ocalized manifestation of a systemic process, and subtle
athogenic features are exhibited by remote venous tissue
uch as the IMV. These tissues may be more informative
han established end-stage aortic wall in defining early





or fragment Theoretic function
5.96 Whole protein Structural
6.64 Whole protein Cell signaling
5.57 Whole protein Cell cycle initiation
5.06 Fragment Structural
ion. Error bars demonstrated 95% confidence interval.teins
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ing left colonic resection. The present study utilized a
control group with no features of active inflammation or
disseminated malignancy.
Interpreting the findings of proteomic analysis is miti-
gated by a limited understanding of the individual role of
implicated proteins within the tissue. Evidence evolves
from proteomic descriptions of changes identified in dis-
ease states and the consequences of protein deficiency
and/or up-regulation. Proteins can be localized to specific
signaling pathways but the interplay between pathways is
complex and incompletely understood. Nevertheless, the
findings of the present study suggest that certain pathways
may play a pivotal role in aneurysm genesis, particularly
with reference to the resistance to oxidative stress and
Fig 3. Immunohistochemically labeled images demon
Staining has been performed on snap-frozen IMV sampl
CD-34 (Endothelial cell); D, cleaved-vimentin; E, prohiinflammation. aOxidative stress is associated with AAA formation in
nimal models and in humans. Oxidant stress is thought to
hange the balance between destruction and regeneration
f the aortic wall by enhancing matrix proteolysis, increas-
ng SMC apoptosis, altering mechanical forces, and aug-
enting the cycle of inflammation.29 Up-regulation of
ADPH oxidase has been detected in conjunction with
ncreased oxidative stress in aortic aneurysm tissue.30 In-
reasing evidence has implicated this reactive oxygen
pecies-generating enzyme in the pathogenesis of AAAs.31
Prohibitin (PHB) is essential for normal mitochondrial
evelopment, and its deficiency is associated with inhibition
f mitochondrial biogenesis and cellular senescence.32 The
est characterized function is as a chaperone involved in
tabilization of mitochondrial proteins.33 PHB constitutes
g protein distribution by cell type in IMV specimen.
h acetone fixation (A, Control; B, -actin (VSMC); C,
F, Annexin A1).stratin
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October 20111106 Nordon et alsion has been shown to decrease accumulation of reactive
oxygen metabolites and decrease oxidative stress induced
cellular permeability.34 In aging and disease, lack of PHB
results in increased reactive oxygen species production and
sensitivity to free radicals.35 These findings translate well
into the current understanding of AAA pathogenesis.
VSMC senescence and oxidative stress are key mechanisms
implicit in AAA formation. The systemic decrease in PHB
in the vasculature of patients with AAA may demonstrate a
widespread cellular senescence and increased vulnerability
to oxidative stress.
AAA development is strongly associated with inflam-
mation and extracellular matrix degradation. Annexin A1
(ANXA1), a protein found to be reduced in the vasculature
of patients with AAA, is involved in the anti-inflammatory
response.36 Interleukin-6 (IL-6) is an inflammatory cyto-
kine that seems to have a pivotal role in the acute-phase
response. Increased venous IL-6 concentrations have been
associated with early aortic dilatations and established
AAAs.37
ANXA1 negatively regulates IL-6 expression. A reduc-
tion in ANXA1 expression has been shown to induce IL-6
expression in healthy tissues. The absence of ANXA1 sig-
nificantly increases IL-6 mRNA and protein expression up
to 200-fold.38 ANXA1 also has phospholipase A2 inhibi-
tory activity, limiting the injurious effect of inflammation.
ANXA1-/- mice demonstrate an exacerbated response to
inflammation, while in a mouse model of AAAs, inhibition
of phospholipase A2 limits aneurysm formation.39 The
decreased ANXA1 in the vasculature of patients with AAAs
may reflect a failure of the cell signaling pathway modulat-
ing inflammation.
Histologic examination of AAAs has revealed a paucity
of medial VSMCs,40 with many cells bearing markers of
apoptosis.41 Apoptosis is a multistep dismantling of cells
led by the activation of caspases. Apoptotic cell death may
contribute to the reduction in cellularity and to the im-
paired repair and maintenance of the extracellular matrix in
AAAs.41 Oxidative stress and inflammation can activate the
apoptotic cascade. Vimentin, an intermediate filament pro-
tein responsible for maintaining cellular integrity, has been
identified as a caspase substrate.42 Vimentin cleavage is a
marker for caspase-9 activation and the initiation of ap-
optosis.43 In the current study, up-regulation of this
caspase-cleaved vimentin fragment was discovered in the
vasculature of AAA patients. Similar to all the protein
changes identified, the expression of this protein appeared
localized to VSMCs, primarily in the media of the IMV.
VSMC apoptosis has been proposed to play a key role in the
pathogenesis of AAA.44 SMC apoptosis is a feature of
developed aneurysms, and now evidence of up-regulated
SMC apoptosis has been found in the vasculature distant
from the AAA.
The majority of research into AAA disease concentrates
on identification of substances that are up-regulated in
AAA and then advocates pharmaco-therapeutic strategies
to inhibit these. Medical management of small aneurysms
have concentrated on -blockade, angiotensin-converting anzyme inhibition, and statin therapy for dyslipidemia.
hese drugs were proposed to have beneficial effects on
AA growth due to hemodynamic properties and bio-
hemical inhibition of matrix metalloprotease (MMP).45
his study is unique in that it identifies specific proteins that
re downregulated. This is highly significant as mechanisms
f treatment based on supplementation of deficient pro-
eins are feasible and they may negate the issues of biolog-
cal redundancy that compromises a strategy of therapeutic
rotein inhibition.
Limitations of study. Whole IMV processing was
sed, rather than a cell specific methodology. This was
erformed as it was thought to provide the most represen-
ative comparative in vivo proteome. The IMV specimens
ere all macroscopically consistent and reproducible pro-
ein concentrations were extracted. No protein depletion
as necessary, as is the case in serum/plasma proteomics,
nd any lipids in the tissue were easily separated by centrif-
gation in lysis buffer. The media of IMV is thin without
lear morphologic distinction from the intima and adven-
itia to facilitate simple stripping in the tissue planes. Laser
apture microdissection may have provided more specific
ell classes, but the protein yield would have been much
educed. SMC culture would not have demonstrated rep-
esentative altered protein expression as the proteome of
he in-culture cells would not translate to in vivo.
Two-D gel electrophoresis provides a reproducible sepa-
ation of proteins. However, it does not resolve all proteins in
he proteome and is biased toward high-abundance proteins.
he dynamic range of protein expression, in combination
ith the variable physicochemical characteristics of the pro-
eins limiting solubility, makes separating all proteins on one
el impossible. This study demonstrated interesting changes
n protein expression, but could never detect them all. Simi-
arly, of the 10 spots deemed appropriate for further iden-
ification, only four could be successfully identified by mass
pectrometry. This is not unusual in human tissue pro-
eomic experiments using 2-D gel electrophoresis where at
est 70% of spots are characterized.46 These protein spots,
dentified by both cyanine labeling and silver staining, are
ensitive to 0.2 ng and 1 ng, respectively. When excised
rom the gel and trypsin digested for identification by MS,
he concentrations may have been below the detection
hreshold, or the samples may have been contaminated
imiting spectral matching. Unfortunately, the spots that
ould not be identified all had very significant fold changes.
n alternative shotgun proteomic approach may be more
ewarding. This methodwould identify a greater number of
roteins in the sample lysate, yet is more reliant on compu-
ational algorithms to interpret the data, which still requires
alidation by a protein-specific technique.
ONCLUSIONS
This experiment provides further evidence of AAAs
epresenting a systemic disease of the vasculature. It has
emonstrated increased VSMC apoptosis and decreased
evels of protein involved in regulation of IL-6 expression at
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found in the tissue of advanced AAAs.
Using proteomic techniques, downregulation of pro-
hibitin and annexin A1 in the vasculature of patients with
AAAs has been identified. Up-regulation of a caspase-
cleaved fragment of vimentin, which is pathognomonic of
cellular apoptosis, is also evident in the vasculature. These
protein changes have been localized to the VSMC in these
tissue samples remote from the AAA free from atheroscle-
rosis. Understanding these changes based on current
knowledge of these proteins identifies decreases in proteins
implicit in pathways required to modulate oxidative stress
and inflammation. These findings provide further evidence
supporting the concept of AAAs representing a systemic
disease of the vasculature. The proteomic changes demon-
strated in this model of early aneurysmal disease may pro-
vide future therapeutic targets to combat AAA develop-
ment.
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1650.6 1705.2Supplemental Fig 6. Annexin A1 spectra.Supplemental Table. Protein identification by mass spectrometry
Spot
No. Protein Accession No.









499 -cardiac actin P68032 1 10.1 1%
677 Annexin A1 P04083 3 28.2 9% 80 .0002
744 Prohibitin P35232 3 30.2 16% 71 .0015
1144 Vimentin P08670 1 10.1 4%MALDI-TOF, matrix-assisted laser desorption/ionization-time of flight, MS, mass spectroscopy.
